scholarly journals Emerging Scholar Award

2021 ◽  
Author(s):  
Catherine Butler
Keyword(s):  
Scholar Award

Complete versus culprit-only PCI in patients with STEMI and multivessel disease: a systematic review and meta-analysis of randomized controlled trials

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
J.Y Levett ◽  
S.B Windle ◽  
K.B Filion ◽  
J Cabaussel ◽  
M.J Eisenberg
Keyword(s):  
Myocardial Infarction ◽  
Systematic Review ◽  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Complete Revascularization ◽  
Funding Source ◽  
Randomized Controlled ◽  
Mcgill University ◽  
Scholar Award

Abstract Background Approximately half of patients with ST-segment elevation myocardial infarction (STEMI) present with multivessel coronary artery disease (CAD) during primary percutaneous coronary intervention (PCI). Purpose To compare the risks of major cardiovascular outcomes and procedural complications in patients with STEMI and multivessel CAD randomized to complete revascularization versus culprit-only PCI. Methods We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing complete to culprit-only PCI, identified via a systematic search of MEDLINE, Embase, and the Cochrane Libraries. Count data were pooled using DerSimonian and Laird random-effects models with inverse variance weighting to obtain relative risks (RRs) and corresponding 95% confidence intervals (CIs). Results A total of 8 RCTs (n=6,632) were included, with mean/median follow-up times ranging from 6 to 36 months. Compared to culprit-only PCI, complete PCI was associated with a substantial reduction in MACE (12.6% vs. 22.0%), repeat myocardial infarction (4.5% vs. 6.9%), and repeat revascularization (3.3% vs. 12.1%) (Table 1). Complete PCI may also improve all-cause and cardiovascular mortality, but estimates were accompanied by wide 95% CIs. Findings for stroke, major bleeding, and contrast-induced AKI were inconclusive. Conclusion Complete revascularization appears to confer benefit over culprit-only PCI in patients with STEMI and multivessel CAD, and should be considered a first-line strategy in these patients. Funding Acknowledgement Type of funding source: Public Institution(s). Main funding source(s): Mr. Levett is supported by a Dr. Clarke K. McLeod Memorial Scholarship, funded through the McGill University Faculty of Medicine Research Bursary Program. Dr. Filion is supported by a Junior 2 Research Scholar award from the Fonds de recherche du Québec – Santé and a William Dawson Scholar award from McGill University.

scholarly journals Four outstanding young Chinese scientists received the 2013 Scholar Award from the US Chinese Anti-Cancer Association and the National Foundation for Cancer Research

2013 ◽  
Vol 32 (12) ◽  
pp. 631-635 ◽  
Author(s):  
Lifang Hou ◽  
Li Yan ◽  
Wei Zhang ◽  
Michael Yi Wang ◽  
Shi-Yuan Cheng
Keyword(s):  
Cancer Research ◽  
National Foundation ◽  
Anti Cancer ◽  
The Us ◽  
Scholar Award
Sign in / Sign up

Export Citation Format

Share Document